ERBB2 and neoplasm: Therapeutic targets tested in initial phase I/II trials included interleukin-13 receptor subunit alpha-2 (IL-13Rα2) [128,129], EGFRvIII [130,131], and human epidermal growth factor receptor 2 (HER2) [132], chosen because of the selective expression in tumor cells compared to healthy brain cells.